(Reuters) – Merck & Co is in late-stage talks to acquire Prometheus Biosciences Inc to get its hands on promising immune disease treatments, the Wall Street Journal reported on Sunday citing people familiar with the matter.
(Reporting by Kanjyik Ghosh in Bengaluru; Editing by Tom Hogue)
